Pathogenic T Helper Type 17 Cells Contribute to Type 1 Diabetes Independently of Interleukin-22

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2015 Oct 27

PMID 26496462

Citations 21

Authors

S M Bellemore

E Nikoopour

O Krougly

E Lee-Chan

L A Fouser

B Singh

Affiliations

Soon will be listed here.

Abstract

We have shown that pathogenic T helper type 17 (Th17) cells differentiated from naive CD4(+) T cells of BDC2·5 T cell receptor transgenic non-obese diabetic (NOD) mice by interleukin (IL)-23 plus IL-6 produce IL-17, IL-22 and induce type 1 diabetes (T1D). Neutralizing interferon (IFN)-γ during the polarization process leads to a significant increase in IL-22 production by these Th17 cells. We also isolated IL-22-producing Th17 cells from the pancreas of wild-type diabetic NOD mice. IL-27 also blocked IL-22 production from diabetogenic Th17 cells. To determine the functional role of IL-22 produced by pathogenic Th17 cells in T1D we neutralized IL-22 in vivo by using anti-IL-22 monoclonal antibody. We found that blocking IL-22 did not alter significantly adoptive transfer of disease by pathogenic Th17 cells. Therefore, IL-22 is not required for T1D pathogenesis. The IL-22Rα receptor for IL-22 however, increased in the pancreas of NOD mice during disease progression and based upon our and other studies we suggest that IL-22 may have a regenerative and protective role in the pancreatic islets.

Citing Articles

Epigenetic modulation of selected immune response genes and altered functions of T lymphocytes and macrophages collectively contribute to autoimmune diabetes protection.

Jayaraman A, Arianas M, Jayaraman S BBA Adv. 2023; 1:100031.

PMID: 37082012 PMC: 10074972. DOI: 10.1016/j.bbadva.2021.100031.

Insights in diabetes: Molecular mechanisms-Protectin DX, an anti-inflammatory and a stimulator of inflammation resolution metabolite of docosahexaenoic acid, protects against the development of streptozotocin-induced type 1 and type 2 diabetes....

Rengachar P, Polavarapu S, Das U Front Endocrinol (Lausanne). 2023; 13:1053879.

PMID: 36778598 PMC: 9908003. DOI: 10.3389/fendo.2022.1053879.

Exenatide regulates Th17/Treg balance via PI3K/Akt/FoxO1 pathway in db/db mice.

Xu Q, Zhang X, Li T, Shao S Mol Med. 2022; 28(1):144.

PMID: 36463128 PMC: 9719171. DOI: 10.1186/s10020-022-00574-6.

Therapeutic Opportunities of IL-22 in Non-Alcoholic Fatty Liver Disease: From Molecular Mechanisms to Clinical Applications.

Zai W, Chen W, Liu H, Ju D Biomedicines. 2021; 9(12).

PMID: 34944732 PMC: 8698419. DOI: 10.3390/biomedicines9121912.

CCL24 Protects Renal Function by Controlling Inflammation in Podocytes.

Wang Y, Wu X, Geng M, Ding J, Lv K, Du H Dis Markers. 2021; 2021:8837825.

PMID: 34221188 PMC: 8221868. DOI: 10.1155/2021/8837825.

References

Bhattacharya S, Ray R, Johnson L . Decreased apoptosis in polyamine depleted IEC-6 cells depends on Akt-mediated NF-kappaB activation but not GSK3beta activity. Apoptosis. 2005; 10(4):759-76. DOI: 10.1007/s10495-005-2943-3. View

Jia L, Wu C . The biology and functions of Th22 cells. Adv Exp Med Biol. 2014; 841:209-30. DOI: 10.1007/978-94-017-9487-9_8. View

Bellemore S, Nikoopour E, Schwartz J, Krougly O, Lee-Chan E, Singh B . Preventative role of interleukin-17 producing regulatory T helper type 17 (Treg 17) cells in type 1 diabetes in non-obese diabetic mice. Clin Exp Immunol. 2015; 182(3):261-9. PMC: 4636888. DOI: 10.1111/cei.12691. View

Sugita S, Kawazoe Y, Imai A, Yamada Y, Horie S, Mochizuki M . Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease. Arthritis Res Ther. 2012; 14(3):R99. PMC: 3446476. DOI: 10.1186/ar3824. View

Xue J, Nguyen D, Habtezion A . Aryl hydrocarbon receptor regulates pancreatic IL-22 production and protects mice from acute pancreatitis. Gastroenterology. 2012; 143(6):1670-80. PMC: 3647696. DOI: 10.1053/j.gastro.2012.08.051. View

Singh B, Nikoopour E, Huszarik K, Elliott J, Jevnikar A . Immunomodulation and regeneration of islet Beta cells by cytokines in autoimmune type 1 diabetes. J Interferon Cytokine Res. 2011; 31(10):711-9. DOI: 10.1089/jir.2011.0025. View

Sonnenberg G, Fouser L, Artis D . Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol. 2011; 12(5):383-90. DOI: 10.1038/ni.2025. View

Nikoopour E, Bellemore S, Singh B . IL-22, cell regeneration and autoimmunity. Cytokine. 2014; 74(1):35-42. DOI: 10.1016/j.cyto.2014.09.007. View

Stadinski B, Delong T, Reisdorph N, Reisdorph R, Powell R, Armstrong M . Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol. 2010; 11(3):225-31. PMC: 3166626. DOI: 10.1038/ni.1844. View

10.

Ma H, Liang S, Li J, Napierata L, Brown T, Benoit S . IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest. 2008; 118(2):597-607. PMC: 2200300. DOI: 10.1172/JCI33263. View

11.

Nikoopour E, Sandrock C, Huszarik K, Krougly O, Lee-Chan E, Masteller E . Cutting edge: vasostatin-1-derived peptide ChgA29-42 is an antigenic epitope of diabetogenic BDC2.5 T cells in nonobese diabetic mice. J Immunol. 2011; 186(7):3831-5. DOI: 10.4049/jimmunol.1003617. View

12.

Shioya M, Andoh A, Kakinoki S, Nishida A, Fujiyama Y . Interleukin 22 receptor 1 expression in pancreas islets. Pancreas. 2008; 36(2):197-9. DOI: 10.1097/MPA.0b013e3181594258. View

13.

Hill T, Krougly O, Nikoopour E, Bellemore S, Lee-Chan E, Fouser L . The involvement of interleukin-22 in the expression of pancreatic beta cell regenerative Reg genes. Cell Regen. 2014; 2(1):2. PMC: 4230743. DOI: 10.1186/2045-9769-2-2. View

14.

Diveu C, McGeachy M, Boniface K, Stumhofer J, Sathe M, Joyce-Shaikh B . IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J Immunol. 2009; 182(9):5748-56. DOI: 10.4049/jimmunol.0801162. View

15.

Gurney A . IL-22, a Th1 cytokine that targets the pancreas and select other peripheral tissues. Int Immunopharmacol. 2004; 4(5):669-77. DOI: 10.1016/j.intimp.2004.01.016. View

16.

Ishigame H, Zenewicz L, Sanjabi S, Licona-Limon P, Nakayama M, Leonard W . Excessive Th1 responses due to the absence of TGF-β signaling cause autoimmune diabetes and dysregulated Treg cell homeostasis. Proc Natl Acad Sci U S A. 2013; 110(17):6961-6. PMC: 3637710. DOI: 10.1073/pnas.1304498110. View

17.

Dudakov J, Hanash A, van den Brink M . Interleukin-22: immunobiology and pathology. Annu Rev Immunol. 2015; 33:747-85. PMC: 4407497. DOI: 10.1146/annurev-immunol-032414-112123. View

18.

Rutz S, Eidenschenk C, Ouyang W . IL-22, not simply a Th17 cytokine. Immunol Rev. 2013; 252(1):116-32. DOI: 10.1111/imr.12027. View

19.

Haskins K, Cooke A . CD4 T cells and their antigens in the pathogenesis of autoimmune diabetes. Curr Opin Immunol. 2011; 23(6):739-45. PMC: 3940273. DOI: 10.1016/j.coi.2011.08.004. View

20.

Aggarwal S, Xie M, Maruoka M, Foster J, Gurney A . Acinar cells of the pancreas are a target of interleukin-22. J Interferon Cytokine Res. 2002; 21(12):1047-53. DOI: 10.1089/107999001317205178. View